Why Most Medical Research Is Funded by the Industry It Studies
December 17, 2025 · Frisian News
Pharmaceutical and medical device companies now fund the majority of clinical research in wealthy nations, creating conflicts of interest that shape which treatments get studied and promoted. Independent funding for medical research has collapsed as governments cut budgets and universities turn to industry partnerships.
A researcher at a major university publishes results showing a new heart medication works better than existing drugs. The funding line at the bottom of the paper reveals the source: the company that makes the new drug paid for the entire study. This scenario has become normal in medical science. Pharmaceutical firms and medical device makers now fund roughly 60 percent of all clinical research in the United States, and the numbers run similar in other wealthy countries. Universities and independent research institutes, starved of public money, have become dependent on corporate cash.
The problem runs deeper than simple bias. When a company funds research into its own product, it chooses the researchers, sets the research question, and often controls what gets published. Negative results about the company's drug rarely see the light of day. A 2022 study in JAMA found that trials funded by pharmaceutical firms reported favorable outcomes three times more often than independently funded trials testing the same drugs. The effect is real and measurable. Doctors and patients read these published results and make treatment decisions based on incomplete information.
Government funding for basic medical research has flatlined for two decades in most wealthy nations. The National Institutes of Health's budget, adjusted for inflation, is smaller now than it was in 2003. Universities responded by cutting their own research budgets and leaning hard on industry partnerships. A professor who wants to run a study now often needs corporate sponsorship to cover the costs. This gives pharmaceutical companies enormous power over which diseases get studied, which treatments get compared, and which side effects get highlighted. Research into cheap generic drugs or prevention strategies? Companies won't fund it. Research into expensive new pills? They fund it generously.
The bias extends beyond the numbers. Companies design studies to make their drugs look good. They run their medication against placebos rather than against competing treatments. They choose patient populations most likely to benefit. They measure outcomes that favor their product. Regulators know this happens, and yet they rely almost entirely on industry-funded studies to decide whether to approve new drugs. The fox watches the henhouse, and everyone pretends this is normal.
Some countries have tried to break the cycle. The British National Health Service funds its own research network. Germany and Scandinavia have stronger public research budgets. But these remain exceptions. In the United States and much of the English-speaking world, the pharmaceutical industry now runs medical science. Doctors practice medicine based on research they did not fund and did not design. Patients take drugs approved based on evidence shaped by corporate interests. The system works well for companies. For everyone else, the question remains unanswered: what would we learn if we actually studied these drugs independently?
In ûndersiker oan in grutte universiteit publisearret resultaten dy't sjen litte dat in nij hartmedisin better wurket as besteande geneesmiddels. De finansjeringsliny ûnder oan it artikel onthûlet de boarne: it bedriuw dat it nije geneesmiddel makket betelle it heulste ûndersyk. Dit senario is no normaal yn medyske wittenskip. Farmasyske bedrijven en medyske fabrikanten betelle no omtrint 60 persint fan alle klinsk ûndersiken yn de Feriene Steaten, en de sifers binne fergelykber yn oare welstannde lannen. Universiteiten en ûnôfhinklike ûndersykinstituten, útput fan iepenbuer jild, binne ôfhinklik wurden fan bedrijfskassen.
It probleem giet dipper as ienfâldige foarynôm. As in bedriuw ûndersyk nei syn eigen produkt finansjeret, kiest it de ûnderskers, stelt it de ûndersykfraach en kontrolearret it faak wat publiseare wurde. Negative resultaten oer it geneesmiddel fan it bedriuw sjogge selden it deirlicht. In studzje út 2022 yn JAMA fûn dat ûndersiken finansjere troch farmasyske bedrijven gûnstich útkomsten trije kear faker rapportearen as ûnôfhinklik finansjere ûndersiken dy't deselde geneesmiddels testen. It effekt is wirklik en mjitber. Doktoren en pasjinten lêze dizze publisearre resultaten en nimme behannelingsbeslitengen op basis fan ûnfolsleine ynformaasje.
Regearingsmiddels foar fûndasjoneel medysk ûndersyk binne twa desennia lang gelyk bleven yn de measte welstannde lannen. It budget fan 'e National Institutes of Health, korrizjearre foar ynflaasje, is no lytser as yn 2003. Universiteiten reagearren troch har eigen ûndersykbegreting te snijen en swier op yndustriële partnerskip fertrouwe. In professor dy't in ûndersyk útfiere wol hat no faak bedrijfssteun nedich om de kosten te dekken. Dit jout farmasyske bedrijven enorme macht oer hokker siken ûndersocht wurde, hokke behanneling ferliken wurde en hokke nebiereksten ûnder de oandacht brocht wurde. Ûndersyk nei goedkeap generike geneesmiddels of ferfoegingsstrategyën? Bedrijven wolle dit net finansjere. Ûndersyk nei duore nije pillen? Se finansjere it rûsich.
De foarynôm geit fierder as de sifers. Bedrijven ûntwerpe ûndersiken om har geneesmiddels goed út te litten. Se stelle har medysin tsjin plasebo's ynstee fan tsjin konkurrearne behanneling. Se kieze pasjintenpopulaasjes dy't it meast tsjinnes profitearje. Se mjitte resultaten dy't har produkt begûnstichje. Regelearen wite dat dit bart, en dochs fertrouwe se hast folslein op troch de yndustry finansjere ûndersiken om te beslikken oft se nije geneesmiddels goetkeurje. De fox bewakt de kipchenhoeke, en elkenien dogge asof dit normaal is.
Sommige lannen hawwe besocht de sirkel te brekken. De Britske National Health Service finansjert har eigen ûndersyknetwork. Dútslân en Skandinaafje hawwe sterker iepenbuer ûndersykbegreting. Mar dit binne útsûnderingen. Yn de Feriene Steaten en folle fan 'e Ingelsksprekende wrâld fiert de farmasyske yndustry no medyske wittenskip út. Doktoren oefenje geneeskunde út op basis fan ûndersyk dat se net finansjere hawwe en net ûntworpen hawwe. Pasjinten nimme geneesmiddels wêrfan de goetkeurin op bewiis based is dat troch bedrijfsbelangen foarme is. It systeem wurket goed foar bedrijven. Foar elkenien oars bliuwt de fraach beantwurde: wat soene wy learre ast dizze geneesmiddels wirklik ûnôfhinklik ûndersochten?
Published December 17, 2025 · Frisian News · Ljouwert, Fryslân